Statistical methods in hematology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Kaplan-Meier estimation
Time-to-event endpoints
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Non-inferiority trial design
All hematology trials
19 results
- ALLIANCE A041202Independent statistical analysis of ALLIANCE A041202, a randomized phase 3 trial comparing rituximab and bendamustine hydrochloride, ibrutinib, or ibrutinib plus rituximab in older patients with previously untreated chronic lymphocytic leukemia.
- AUGMENTIndependent statistical analysis of the phase 3 AUGMENT trial of rituximab plus lenalidomide versus rituximab plus placebo in relapsed or refractory indolent non-Hodgkin's lymphoma, including progression-free survival, overall survival, response endpoints, statistical…
- BELINDAIndependent statistical analysis of the BELINDA phase 3 trial of tisagenlecleucel in adult patients with aggressive B-cell non-Hodgkin lymphoma, including trial design, event-free survival methodology, hazard ratio interpretation, confidence intervals, and statistical…
- BOSTONIndependent statistical analysis of the phase 3 BOSTON trial of selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in multiple myeloma, including PFS, response, overall survival, safety, and statistical methodology.
- CAPTIVATEIndependent statistical analysis of CAPTIVATE (NCT02910583), a randomized phase 2 trial of ibrutinib plus venetoclax in treatment-naive chronic lymphocytic leukemia and small lymphocytic lymphoma, including its primary endpoints, statistical methods, and interpretation.
- CASSIOPEIAA complete statistical analysis of the phase 3 CASSIOPEIA trial evaluating daratumumab in transplant-eligible participants with previously untreated multiple myeloma, including trial design, primary endpoints, reported statistical analyses, safety, and interpretation.
- CLL14Independent statistical analysis of the CLL14 phase 3 trial comparing obinutuzumab plus venetoclax with obinutuzumab plus chlorambucil in chronic lymphocytic leukemia, including time-to-event and response analyses.
- E1912Independent statistical analysis of E1912 (NCT02048813), a randomized phase 3 trial comparing ibrutinib and rituximab with fludarabine, cyclophosphamide, and rituximab in untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
- ENDEAVORIndependent statistical analysis of the ENDEAVOR phase 3 trial of carfilzomib and dexamethasone versus bortezomib and dexamethasone in relapsed multiple myeloma, including progression-free survival, overall survival, response, safety, and statistical methodology.
- ENESTndIndependent statistical analysis of ENESTnd (NCT00471497), a randomized phase 3 study comparing nilotinib with imatinib in adults with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.
- GADOLINIndependent statistical analysis of the phase 3 GADOLIN trial of obinutuzumab plus bendamustine versus bendamustine alone in participants with rituximab-refractory, indolent non-Hodgkin's lymphoma.
- GOYAIndependent statistical analysis of the GOYA phase 3 trial of obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in participants with CD20-positive diffuse large B-cell lymphoma, including trial design, progression-free survival, statistical methodology,…
- ICARIA-MMIndependent statistical analysis of the phase 3 ICARIA-MM trial comparing isatuximab, pomalidomide, and dexamethasone with pomalidomide and dexamethasone in refractory or relapsed and refractory multiple myeloma.
- QUAZAR AML-001Independent statistical analysis of QUAZAR AML-001, a randomized phase 3 trial of oral azacitidine plus best supportive care versus placebo plus best supportive care as maintenance therapy in acute myeloid leukemia in…
- RED-HFIndependent statistical analysis of the RED-HF phase 3 trial of darbepoetin alfa in heart failure, including trial design, time-to-event endpoints, hazard ratios, KCCQ analyses, safety, methodology, and statistical interpretation.
- SEQUOIAIndependent statistical analysis of the phase 3 SEQUOIA trial comparing zanubrutinib with bendamustine plus rituximab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma, including its progression-free survival analysis and statistical…
- SWOG S0777Independent statistical analysis of SWOG S0777 (NCT00644228), a randomized phase 3 trial of lenalidomide and dexamethasone with or without bortezomib in previously untreated multiple myeloma.
- VIALE-AIndependent statistical analysis of the phase 3 VIALE-A trial of venetoclax plus azacitidine versus azacitidine in treatment-naive participants with acute myeloid leukemia who are ineligible for standard induction therapy.
- ZUMA-7Independent statistical analysis of ZUMA-7, the randomized phase 3 trial of axicabtagene ciloleucel versus standard of care therapy in relapsed/refractory diffuse large B-cell lymphoma, including event-free survival, response, overall survival, quality of…